Aim: To assess the impact of faster aspart vs insulin aspart on long-term clinical outcomes and costs for patients with type 1 diabetes mellitus (T1DM) in the UK setting.
| INTRODUCTION
It has been estimated that there are 370 000 adults and 26 500 children living with type 1 diabetes mellitus (T1DM) in the UK. 1, 2 Patients with T1DM are at a higher risk of chronic complications and mortality than people without diabetes of the same age. 3 In 2010/ 2011, the direct costs attributable to T1DM in the UK were approximately £1 bn. 4 In addition, it is estimated that 830 000 sick days are taken per year as a result of T1DM, leading to indirect costs of approximately £0.9 bn. Projections suggest that, if no changes are made to treatment patterns, direct and indirect costs will increase to £1.8 and £2.4 bn, respectively, by 2035/2036. 4 Long-term studies in patients with T1DM, such as the Diabetes
Control and Complications Trial (DCCT) and the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study,
suggest that improving glycaemic control can reduce the incidence of diabetes-related complications, lowering the clinical and economic burden of the disease. 5, 6 In the UK in 2015, however, only 29.9% of patients with T1DM were achieving the glycaemic control target of glycated haemoglobin (HbA1c) < 7.5%. 7 This target has recently been lowered to 6.5% by the National Institute for Health and Care Excellence (NICE), and whilst no data have been published on the proportion of patients achieving the revised target, it is likely to be lower than for the previous guidance. Fast-acting insulin aspart (faster aspart) is conventional insulin aspart (insulin aspart) in a new formulation for the treatment of diabetes requiring insulin. Faster aspart has been developed to have a faster onset of action which more closely matches physiological secretion of endogenous insulin. 8 When compared with insulin aspart, faster aspart has a twice faster onset of appearance in the bloodstream, a twice higher insulin exposure within the first 30 minutes and a 74% greater glucose-lowering effect in the first 30 minutes after administration. 9 "Onset 1" was a 26-week multicentre, multinational, double-blind trial in patients with T1DM in which faster aspart was compared with insulin aspart, both in combination with insulin detemir in a basalbolus insulin regimen. 10 The 
| Model description
The analysis was performed using the QuintilesIMS CORE Diabetes
Model. 12 This model is a validated, non-product-specific diabetes policy analysis tool and is based on a series of interdependent submo- to capture all relevant long-term complications and associated costs and assess their impact on life expectancy and quality-adjusted life expectancy, consistent with good practice guidance for economic evaluation of interventions for diabetes. 16 Future clinical benefits and costs were discounted at 3.5% annually, based on health economic guidance for the UK setting. 17 
| Simulated cohort and treatment effects
The baseline cohort characteristics applied in the analysis were based on all patients included in the onset 1 study. 10 The mean (standard deviation [s.d.]) age was 44.4 (13.9) years, with mean duration of diabetes of 19.9 (12.3) years, and mean HbA1c of 7.6 (0.7)%. The proportion of patients using tobacco products was based on the trial data, but the number of cigarettes smoked per day was assumed to be the same as the general UK population and was based on countryspecific data, as was alcohol consumption. 18, 19 Treatment effects applied in the faster aspart and insulin aspart arms (both in combination with insulin detemir) were taken from the 26-week main phase of the trial, in line with the primary endpoint, with data from mealtime insulin administration used (Table 1) . Modelled data were used to account for any differences in the baseline cohort characteristics between the treatment arms. 10 After application of the treatment effects in the first year of the analysis, HbA1c was assumed to remain constant over time. There are currently no published progression equations for HbA1c in patients with T1DM, and data from long-term studies such as DCCT and EDIC suggest that HbA1c does not increase as patients age. 6 Unlike type 2 diabetes mellitus (T2DM), T1DM is not a progressive disease and it is unlikely that substantial changes in HbA1c over time would be observed. Patients were assumed to receive faster aspart plus insulin detemir or insulin aspart plus insulin detemir for the duration of their lifetimes, with no treatment switching applied. . [34] [35] [36] [37] For disutilities applied after non-severe hypoglycaemic events, a diminishing disutility approach as described by Lauridsen et al. 38 was used. This approach was chosen as there is evidence that the marginal impact of non-severe hypoglycaemia on quality of life falls as the frequency of hypoglycaemic events increases.
| Costs and utilities

| Sensitivity analyses
Sensitivity analyses were conducted to evaluate the key drivers of outcomes and to assess the effect of changes in modelling assumptions on the projected outcomes. The influence of time horizon on the outcomes projected by the model was investigated by running analyses over 10, 20 and 30 years. It should be noted that a time horizon of 70 years was required for all modelled patients to have died, and therefore shorter time horizons do not capture all complications and costs. To examine the effect of discounting on outcomes, simulations were performed with (symmetric) discount rates of 0% and 6%. A total of five simulations were run to assess the key drivers of clinical benefit associated with faster aspart. In the faster aspart arm, changes in HbA1c, blood pressure, serum lipids, body mass index and hypoglycaemic events were set to the value in the insulin aspart arm in turn. A further analysis with only the statistically significant difference in HbA1c applied in the faster aspart arm, with all other parameters equal to the insulin aspart arm, was conducted.
To evaluate the impact of alternative assumptions around longterm parameter progression on projected outcomes, 5 sensitivity analyses were conducted. In the base case analysis, the difference in HbA1c between the treatment arms was assumed to persist for the entire simulation, with sensitivity analyses conducted with the difference abolished after 1, 5 and 10 years. A further analysis was conducted with the HbA1c difference abolished linearly over 10 years (ie, the difference between the treatment arms disappeared gradually). A final analysis was conducted with HbA1c difference between the treatment arms maintained for the duration of patient lifetimes, but an increase of 0.045% per year was applied in both arms, based on data from the DCCT. 5 This analysis reflects that patients with T1DM may develop some characteristics of T2DM due to weight gain and family history. In contrast to T1DM, T2DM is a progressive disease, with insulin resistance increasing and β-cell function declining over time.
The effect of over-or underestimating the direct cost of treating diabetes-related complications was investigated in 2 scenarios, by increasing and decreasing costs of complications by 20%. The base case analysis was conducted using a diminishing disutility approach for non-severe hypoglycaemic events, and a sensitivity analysis was conducted using a static disutility approach with disutilities applied based on T1DM-specific data from Evans et al. 32, 38 The impact of hypoglycaemia disutilities was further explored in an analysis with no disutility applied after severe and non-severe events. 39 In a further sensitivity analysis to examine structural uncertainty, a combined mortality risk equation was applied. 40 Reflecting the primary endpoint of onset 1, the 26-week data were applied in the base case analysis. The 52-week data, including the additional 26-week treatment period, were used in a sensitivity analysis with equivalent assumptions. An analysis was also conducted with the 26-week data applied in the first year of the analysis, and then treatment effects were applied to bring parameters to the values seen at 52 weeks in the second year of the analysis (the QuintilesIMS CORE Diabetes Model uses an annual cycle, and therefore it was not possible to apply changes at 6 months). Probabilistic sensitivity analysis was performed using a second-order Monte Carlo approach with sampling of baseline cohort characteristics, treatment effects, costs and utilities.
3 | RESULTS
| Base case analysis
In the base case analysis, long-term projections showed that faster aspart was associated with improved discounted life expectancy (by 0.11 years) and discounted quality-adjusted life expectancy (by 0.13 quality-adjusted life-years [QALYs]) vs insulin aspart in patients with T1DM (Table 2) . Improved clinical outcomes resulted from a reduced incidence of diabetes-related complications over patient lifetimes ( Figure 1A) . In addition to a reduced incidence of 
| Sensitivity analyses
Faster aspart was associated with improved clinical outcomes and reduced costs from a healthcare payer perspective vs insulin aspart in all sensitivity analyses conducted (Table 3) Using the static approach to disutilities applied after non-severe hypoglycaemic events resulted in reduced quality-adjusted life expectancy in both arms relative to the base case, with the benefit associated with faster aspart falling to 0.12 QALYs. Similarly, when no hypoglycaemia disutilities were applied, the quality-adjusted life expectancy benefit with faster aspart was 0.12 QALYs. Probabilistic sensitivity analysis showed similar mean results to those of the base case, but increased measures of variance around the mean outcomes. Assuming a willingness-to-pay threshold of £20 000 per QALY gained, the analysis indicated that there was an 87.0% probability that faster aspart would be cost-effective vs insulin aspart. The present modelling analysis does not take into account changes in PPG control, as this variable cannot be captured in the QuintilesIMS CORE Diabetes Model. In the onset 1 study, faster aspart was associated with statistically significant improvements in PPG increments compared with insulin aspart. 10 It has been suggested that lower PPG may be associated with a reduced risk of diabetes-related complications, with guidance from the International Diabetes Federation stating that post-meal hyperglycaemia is independently associated with macrovascular disease, ophthalmic disease and cancer. 41 A 2012 review found that higher PPG was associated with increased all-cause and cardiovascular mortality, increased incidence of major cardiovascular events, and progression of diabetic retinopathy. 42 However, the impact of reduced PPG may to some extent be indirectly included in the present analysis, as HbA1c was used as the measure of glycaemic control. Some studies have suggested that PPG makes a significant contribution to HbA1c in patients who are relatively well controlled, although other studies have been more cautious and have suggested that fasting plasma glucose is a better indicator of HbA1c, particularly in patients with a very high HbA1c concentration. 43, 44 In addition to improving glycaemic control, the rapid onset of action of faster aspart and the faster appearance in the bloodstream may provide patients with T1DM with increased flexibility around timing of doses. 8, 9 Currently, mealtime insulins must be injected preprandially, and this may result in hypoglycaemia if the meal is delayed or not consumed. Faster aspart represents a mealtime insulin with the option of post-meal dosing when needed, without compromising glycaemic control compared with insulin aspart. 10 This opportunity for post-meal dosing, when required, may improve convenience, and furthermore, flexibility in the timing of insulin dosing has been shown to be associated with improved quality of life in patients with diabetes, beyond the impact on hypoglycaemic events. 45, 46 The present analysis did not capture the utility of flexible insulin dosing, as data were used from the arms of the trial in which mealtime dosing was specified, but this impact on quality of life may be seen in real-world clinical practice, and remains an area of interest for future research.
| DISCUSSION
A limitation of the present analysis, common to a number of health economic analyses and particularly those for diabetes interventions, was the reliance on relatively short-term clinical trial data to make long-term projections. However, in the absence of long-term trial data, modelled projections represent a valuable source of information for healthcare decision-makers aiming to allocate resources efficiently to maximize healthcare across the population. Furthermore, projecting outcomes over patient lifetimes is recommended in guidelines for economic evaluation of interventions for patients with diabetes. The present analysis aimed to minimize the impact of this by using a model of diabetes based on published long-term epidemiological studies that has been extensively published and validated. 13, 14 A further limitation may be the clinical data used to inform the analysis. The study was based on a randomized controlled trial (onset 1), and therefore there is an assumption that the effects observed in the trial would be transferable to clinical practice in the UK setting. Registry data provide evidence of the impact of interventions in the real world, but it was not possible to use registry data in the present analysis, as, at the time the analysis was conducted, faster aspart was not available in the UK. As faster aspart becomes more widely used, data from registries such as the Clinical Practice Research Datalink could be used to conduct equivalent long-term analyses. Additionally, data from registries would allow the clinical effects to be assessed in a larger patient cohort and over a longer duration than was possible in the onset 1 trial. Nevertheless, the onset 1 trial represents the best data source currently available to inform the present analysis.
Faster aspart has been shown to have a greater glucose-lowering effect within the first 30 minutes after injection compared with insulin aspart because of its faster appearance within the bloodstream, and the onset 1 trial found that this resulted in improved glycaemic control in patients with T1DM. Long-term projections, as part of the present analysis, suggested that treatment with faster aspart plus insulin detemir was likely to improve long-term clinical outcomes for patients with T1DM at a reduced cost from a UK healthcare payer perspective vs insulin aspart plus insulin detemir.
